Pharmaceuticals company Caplin Point Laboratories announced Q1FY25 results: Gross Margin for Q1FY25 is 59.6% vs 55.3% in Q1FY24. EBITDA Margin for Q1FY25 is 35.7% vs 34.0% in Q1FY24, aided by new product launches. Basic EPS increased by 19.8% to Rs 16.32 in Q1FY25 compared to Rs 13.62 in Q1FY24. Cash Flow from Operations in Q1FY25 is Rs 96 crore (EBITDA to Cashflow conversion of 56.4%). Free Cash Flow is Rs 59 crore (after Capex investment of Rs 37 Crores) in Q1FY25 as compared to Rs 37 crore (after capex investment of Rs 51 Crores) in Q1FY24. Geographical revenues: Latin America and Rest of World 83%, US 17%. Caplin Steriles Ltd (“CSL”) Q1FY25 Operating Revenue is at Rs 77.93 crore, with 68.9% Y-o-Y growth. CSL's revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for Q1FY25 in the range of 74% and 26% respectively. As of 30th June 2024, Inventories are at Rs 311.60 crore, Receivables is at 113 days. Free Cash Reserves are at Rs 969.2 crore. Total Liquid Assets of the Company (Inventory + Receivables + Free Cash Reserves) are at Rs 1,849 crore as on 30th June’ 2024 Commenting on the performance, C.C. Paarthipan, Chairman said: Our company continues to be an outlier, whether its taking the road less travelled in Latin America, or focusing on our Cashflow and Bottom line rather than unsustainable or inconsistent top line growth. We’re pleased to report yet another strong set of numbers for this quarter. LatAm is a key driver of growth but we’re now also supported by strong performance from the US. As we embark on launching our own frontend in the US, we remain confident that our pattern of success through taking the road less travelled would repeat itself in the biggest markets in the world as well. Result PDF